Good Distribution Practice (GDP) is the set of regulatory requirements governing how a pharmaceutical product is stored, handled, and transported after it leaves the manufacturer and before it reaches a pharmacy, clinical site, or patient. It covers wholesale distributors, brokers, importers/exporters, and logistics providers that move medicinal products through the supply chain, and it exists to keep a product’s identity, quality, and integrity intact across every handoff — not just its temperature.
For procurement and compliance staff, GDP is the framework that determines what you have to verify before you can rely on a distributor: their license status, their quality system, their ability to document chain-of-custody, and their track record on deviations. This guide covers the full GDP framework. For the temperature-control specifics of moving a product through cold chain — packaging qualification, monitoring, and excursion management — see CASRAI’s dedicated Pharma Cold Chain Logistics guide, which GDP requires but does not by itself fully define.
Good Distribution Practice vs. Good Documentation Practice: Same Acronym, Different Rules
“GDP” is genuinely ambiguous in pharma and life-sciences compliance, and mixing the two up is a common, costly mistake. Good Distribution Practice (this guide) governs the physical supply chain: storage, transport, and distributor operations. Good Documentation Practice is an entirely different, unrelated concept — the record-keeping discipline (contemporaneous, attributable, legible records) applied across clinical trials and manufacturing. See CASRAI’s separate guide on Good Documentation Practices (GDP) in Clinical Trials if that is the concept you are actually looking for. When in doubt, spell it out in your own SOPs and communications — do not rely on the bare acronym.
Who Good Distribution Practice Applies To
- Wholesale distributors and brokers who buy, sell, or arrange the sale of medicinal products without taking physical possession, but who influence where product moves.
- Logistics and transportation providers contracted to move product between manufacturer, distributor, pharmacy, and clinical site — including cold-chain couriers and freight forwarders.
- Importers and exporters of medicinal products, who take on additional verification obligations at the point product crosses a regulatory border.
- Contract warehousing and 3PL operators storing product on behalf of a manufacturer or distributor.
- Hospitals, health systems, and research institutions receiving product are not themselves GDP-regulated distributors in most cases, but they sit at the end of a GDP-governed chain and are expected to verify that what they received was handled correctly — and to continue appropriate storage and handling once custody transfers to them.
Manufacturing itself is governed separately by Good Manufacturing Practice (GMP); GDP begins where GMP-controlled manufacturing ends. CASRAI’s GxP Compliance overview covers how GDP fits alongside GLP, GCP, GMP, and GVP as part of the broader “Good … Practice” family.
The Regulatory Frameworks: EU, US, and International
Unlike GMP or GCP, GDP is not governed by a single harmonized global standard — the specific binding requirements differ by jurisdiction, though the underlying expectations are similar everywhere:
- EU Good Distribution Practice Guidelines (Commission guidelines on Good Distribution Practice of medicinal products for human use, published in the Official Journal of the European Union) set out the EU’s binding requirements for wholesale distribution authorisation holders: a documented quality management system, qualified personnel, suitable premises and equipment, full traceability documentation, controlled operations from receipt through delivery, management of outsourced activities via written contracts, a formal complaints/returns/recalls process, defences against falsified medicines entering the legitimate supply chain, and a regular self-inspection programme.
- United States. There is no single US regulation titled “GDP,” but the same territory is covered through a combination of state Board of Pharmacy wholesale distributor licensing, FDA’s current Good Manufacturing Practice requirements under 21 CFR Part 211 (which extend into manufacturer-controlled storage and shipping), and the Drug Supply Chain Security Act (DSCSA), which layers unit-level product tracing, verification, and eventual interoperable electronic track-and-trace obligations on top of physical distribution controls for prescription drugs moving through the US supply chain.
- WHO guidance. The World Health Organization publishes its own model good distribution practice guidance for pharmaceutical products, which is widely referenced by regulators and manufacturers operating in markets that do not yet have their own binding GDP framework, and which underpins much of the language used in national frameworks worldwide.
The practical implication for a procurement or compliance team working across borders: a distributor’s GDP status in one jurisdiction (an EU wholesale distribution authorisation, for example) is not automatically equivalent to compliance in another, and due diligence needs to check the specific licensing and inspection record relevant to where the product is actually moving.
The Core Requirements of a GDP-Compliant Operation
Despite jurisdictional differences, a GDP-compliant distributor is expected to demonstrate the same core set of controls:
- Quality management system. A documented system defining responsibilities, a quality policy, and management review — the same underlying logic as any GxP quality system, scaled to distribution activities.
- Qualified, trained personnel. A named responsible person (in the EU framework, a formally designated Responsible Person) accountable for GDP compliance, plus documented, role-specific training for everyone handling product.
- Suitable premises and equipment. Storage facilities that are secure, clean, appropriately segregated (quarantine, rejected, recalled, and returned stock kept physically or systematically apart from saleable stock), pest-controlled, and equipped with calibrated monitoring appropriate to the products held — temperature control is one component of this, not the whole of it.
- Documentation and traceability. Written procedures for every GDP-relevant activity, plus records that let a specific batch be traced backward to its source and forward to where it was shipped — the chain-of-custody record an auditor or regulator will ask for first.
- Controlled operations. Defined procedures covering receipt, storage, picking and packing, and delivery, including verification steps at receipt (confirming the shipment matches the order and shows no signs of tampering or damage) before product is accepted into saleable stock.
- Outsourced activities under written quality agreements. Any activity contracted out — transportation, warehousing, repackaging — is covered by a written agreement defining each party’s GDP responsibilities; the distributor of record remains accountable even when the physical work is subcontracted.
- Complaints, returns, and recalls. A documented process for receiving and investigating complaints, handling product returns (with clear criteria for what can and cannot go back into saleable stock), and executing a recall effectively and, where required, on short notice.
- Falsified/counterfeit medicine prevention. Procedures for identifying and immediately quarantining suspected falsified product, and for verifying the legitimacy of suppliers before purchasing from them — a requirement that has become more prominent as supply chains have globalized and unit-level serialization (DSCSA in the US, the EU Falsified Medicines Directive’s safety features) has rolled out.
- Self-inspection. A recurring internal audit programme that checks the distributor’s own compliance against its written procedures and the applicable GDP framework, and drives corrective action before an external inspection does.
Standard Operating Procedures Required Under GDP
A GDP-compliant SOP library typically needs to cover, at minimum: receipt and inspection of incoming goods; storage conditions and segregation (including any temperature-controlled storage — see the cold chain logistics guide for that specific set of procedures); order picking, packing, and dispatch; transportation qualification and carrier management; handling of returns; complaint intake and investigation; product recall execution; supplier and customer qualification; deviation and change control; and self-inspection/internal audit. Each SOP needs a defined owner, a review cycle, and evidence that staff were trained on the current version — an SOP that exists on paper but that nobody was trained on is one of the most common findings in a GDP inspection.
Qualifying and Auditing a Distributor
For a procurement or compliance team responsible for a distributor relationship, GDP due diligence generally has three parts:
- Initial qualification. Verify the distributor’s license/authorisation status with the relevant regulator, review their quality system documentation (or a summary/certificate where a full audit is not practical), and confirm they can meet the specific storage and transport conditions your products require.
- A written quality agreement. Defines which party is responsible for what — temperature monitoring, deviation notification timelines, documentation retention, right-to-audit — before product starts moving, not after a problem surfaces.
- Ongoing monitoring and periodic re-audit. GDP status is not a one-time check. A re-qualification cadence (commonly annual or risk-based), a mechanism for the distributor to notify you of deviations or recalls affecting your product, and a periodic on-site or documentation-based audit keep the relationship inspection-ready rather than assumed-compliant.
This is closely related to broader supply-chain and vendor-management practice covered in CASRAI’s Hospital Supply Chain guide, and to the manufacturing-side counterpart in the GMP Audit Checklist for teams that also qualify manufacturing sites.
How GDP Relates to GMP and the Rest of GxP
GDP sits downstream of GMP in a product’s lifecycle: GMP governs how a drug, biologic, or device component is manufactured, tested, and released; GDP takes over the moment that product leaves manufacturer control and governs everything that happens to it — storage, transport, handoffs — until it reaches its end point. The two frameworks are designed to work together end to end, and a documented, uncorrected gap at the GDP stage (an unmonitored storage excursion, a broken chain-of-custody record, an unverified supplier) can undermine a product that was manufactured correctly. See CASRAI’s GxP Compliance guide for how GDP fits alongside GLP, GCP, GMP, and GVP as a family, and the GMP guide for the manufacturing-side requirements that precede GDP.
Frequently Asked Questions
What does GDP compliance actually require day to day?
In practice, GDP compliance means operating against written SOPs for every distribution activity, keeping personnel trained on the current version of those procedures, maintaining traceable records from receipt through delivery, holding a valid distributor license/authorisation, and running a self-inspection programme that catches gaps before a regulator does. For organizations receiving product rather than distributing it, compliance mainly means verifying incoming shipments and maintaining appropriate storage once custody transfers.
Is there an FDA regulation specifically called Good Distribution Practice?
Not as a single named regulation the way GMP has 21 CFR Parts 210/211. In the US, the GDP-equivalent territory is covered through a combination of state Board of Pharmacy wholesale distributor licensing, FDA’s manufacturer-side storage and shipping controls under 21 CFR Part 211, and the Drug Supply Chain Security Act (DSCSA), which adds unit-level product tracing and verification requirements across the distribution chain.
Where can I find the official Good Distribution Practice guidelines?
In the EU, the binding text is the Commission’s guidelines on Good Distribution Practice of medicinal products for human use, published in the Official Journal of the European Union. In the US, the relevant requirements are spread across DSCSA, FDA manufacturer-side regulations, and individual state pharmacy board licensing rules rather than one consolidated GDP document. The World Health Organization also publishes model GDP guidance referenced internationally.
Do I need a dedicated GDP SOP library, or can I fold it into an existing quality system?
Either can satisfy GDP, provided the required procedures — receipt/inspection, storage and segregation, transportation, returns, complaints, recalls, supplier/customer qualification, deviation handling, and self-inspection — are all actually documented, current, and trained-on. Many organizations fold GDP procedures into a broader GxP-aligned quality management system rather than maintaining it as a separate silo, particularly where the same staff also handle GMP- or GCP-adjacent work.
Does Good Distribution Practice only apply to temperature-sensitive products?
No. GDP applies to the full range of medicinal products moving through the supply chain, not only cold-chain products. Temperature control is one requirement among several — security, segregation, documentation, falsified-medicine prevention, and traceability apply just as much to a product stored at controlled room temperature as to a refrigerated biologic.
